NDA 017031 · Laboratoire Hra
Opill
Norgestrel · Oral
Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1973
Oct 23, 1973
Approved uses
2
Original approval plus efficacy supplements
Registered trials
174
43 Phase 3, 9 recruiting
FAERS reports
1,356
302 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 6, 2026.
Use To prevent pregnancy
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 13, 2023 Supplement 41 · Efficacy Summary ReviewLetterLabel
- Oct 23, 1973 Original approval · Type 3 - New Dosage Form
1 products under this application
- OPILL · NORGESTREL 0.075MG · TABLET, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Norgestrel" as an intervention, any sponsor and status, largest first.
- The Evidence for Contraceptive Options and HIV Outcomes TrialPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT02550067 · 7,830 participants · Start Dec 14, 2015 · Primary completion Oct 31, 2018
Drug: DMPA; LNG and 1 more · For: HIV; Contraception
Sites: Manzini, Eswatini; Kisumu, Kenya; Brits, South Africa · 12 sites in all
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral ContraceptivePivotal-lookingCompleted
Duramed ResearchIndustry
NCT00196326 · 2,235 participants · Start Jun 2005 · Primary completion Jun 2007
Drug: DR-1011 · For: Contraception
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 55 sites in all
- Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency ContraceptionPivotal-lookingCompleted
HRA PharmaIndustry
NCT00551616 · 2,221 participants · Start Apr 2007 · Primary completion Apr 2009
Drug: CDB-2914; Levonorgestrel · For: Contraception
Sites: Los Angeles, California; Santa Monica, California; Boulder, Colorado · 33 sites in all
- Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral ContraceptionPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00245921 · 2,000 participants · Start Feb 2003 · Primary completion Oct 2005
Drug: Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg · For: Contraception
- A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible ContraceptionPivotal-lookingTerminated
Medicines360Academic, hospital or other
NCT00995150 · 1,910 participants · Start Nov 2009 · Primary completion Oct 12, 2021
Drug: LNG20; Mirena · For: Contraception
Sites: Phoenix, Arizona; Palo Alto, California; San Francisco, California · 25 sites in all
- Efficacy Trial of CDB 2914 for Emergency ContraceptionPivotal-lookingCompleted
University of PittsburghAcademic, hospital or other
NCT00271583 · 1,672 participants · Start Sep 1999
Drug: CDB-2914; levonorgestrel · For: Emergency Contraception
Sites: Los Angeles, California; Denver, Colorado; New York, New York · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- heavy menstrual bleeding245
- pregnancy on oral contraceptive206
- intermenstrual bleeding182
- polymenorrhoea155
- product dose omission issue79
- nausea77
- adverse drug reaction68
- headache66
- weight increased63
- acne53
- dysmenorrhoea52
- menstruation irregular51
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2008 | 1 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 349 |
| 2025 | 937 |
| 2026 | 21 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The norgestrel-T-IUD.
El-Mahgoub S · Contraception 1980 · Clinical Trial, Randomized Controlled Trial
- Interventions for hidradenitis suppurativa.
Ingram JR, Woo PN, Chua SL, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- [Estrogens. Contraceptive therapy].
Sojo-Aranda I, Cortés-Gallegos V · Ginecol Obstet Mex 1995 · Clinical Trial, English Abstract
- Mechanism of action of norgestrel 0.075 mg a progestogen-only pill. I. Effect on ovarian activity.
Glasier A, Edelman A, Creinin MD, et al. · Contraception 2022 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Clinical assessment of a low-oestrogen combined oral contraceptive.
Bye PG, Elstein M · Br Med J 1973 · Clinical Trial
- Oral versus transdermal hormone replacement therapy.
Stevenson JC, Crook D, Godsland IF, et al. · Int J Fertil Menopausal Stud 1993 · Clinical Trial, Comparative Study
Sponsor: Laboratoire Hra
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.